Vancouver, British Columbia – October 07, 2025 – Pangea (CSE:PNGA) (OTC:PNGAF), also referred to as “the Company,” is pleased to present an update on its recent business operations and advancements. This includes the introduction of its peptide product range and the progress in developing its needle-free delivery system, both managed through its wholly owned subsidiary, Amino Innovations.
Peptide Market and Product Portfolio
During the second quarter of 2025, Pangea finalized its acquisition of Amino Innovations Corp., an innovative health and wellness firm specializing in non-injectable peptide treatments. These peptide offerings are formulated to address various conditions such as muscle and joint recuperation, anti-aging, immune system enhancement, dermatological health, improved sleep, and stress reduction, all without requiring prescriptions or injections.
The worldwide market for peptide therapeutics was valued at an estimated USD$117.26 billion in 2024 and is anticipated to grow to USD$260.25 billion by 2030, demonstrating a Compound Annual Growth Rate (CAGR) of 10.77% from 2025 to 2030. In 2024, the North American peptide therapeutics market held a dominant position, commanding 60.21% of the global market share. The United States leads the North American market, driven by substantial biopharmaceutical investments, extensive research and development expenditures, and expedited regulatory clearances. Within the market, the pain management sector is forecasted to experience considerable expansion between 2025 and 2030 based on application. Regarding administration methods, the parenteral segment (delivery via means other than oral) represented the largest revenue share at 84.08% in 2024. (Source: Grand View Research, Peptide Therapeutics Market 2025-2030)
Digital Channels and Early Metrics
Amino Innovations introduced its eCommerce platform in June 2025, facilitating product information, direct-to-consumer orders, and streamlined purchasing. Initial seeding campaigns involving influencers and clinic partners are currently active, with the first user-generated content and testimonials expected in September. The company has partnered with strategic marketing firms to expand native advertising and data-driven social media customer acquisition efforts. Pangea is closely monitoring subscription sign-ups, customer acquisition expenses, and initial customer group trends to enhance long-term customer value.
Initial beta testing determined the top performing products as:
- BPC: a peptide aiding muscle recuperation, joint well-being, and gut equilibrium.
- KPV: a peptide that boosts immune response and moderates inflammation.
- BLUE: a nootropic containing methylene blue, designed to sharpen focus, improve clarity, and provide lasting energy.
All product variations can be ordered via: www.aminoinnovations.com.
Novel Peptide Delivery Systems Pipeline
Amino is progressing with the creation of patch and sublingual (under-the-tongue) delivery methods, which could provide further needle-free choices with strong user adherence and high-grade absorption capabilities. A functional patch prototype was finished in August. In Q4 2025, the Company plans to collaborate with external laboratories to assess bioavailability and effectiveness.
Manufacturing
Every product offered by the Company is produced in the United States at a cGMP-certified facility, ensuring strict compliance with high standards for hygiene, uniformity, and quality. Certain products undergo independent quantitative studies to evaluate characteristics like stability and potency. This evidence-based methodology underscores the Company’s dedication to data-informed product development and open practices.
New Website and Corporate Materials
To more accurately represent Pangea’s health and wellness objectives after acquiring Amino Innovations, the Company has unveiled its updated website and corporate communications. These resources emphasize Pangea’s dedication to groundbreaking, clean-label offerings and an expanding range of nutrition-focused supplements, peptides, and personal care items. The Company anticipates that these updated materials will connect more effectively with investors. The new website and corporate information can be accessed at pangeafood.com.
About Pangea Natural Foods Inc.
Pangea Natural Foods Inc. operates as a North American producer focused on clean-label foodstuffs and pioneering wellness solutions. Via its subsidiary, Amino Innovations, the Company delivers sophisticated, non-injectable peptide treatments designed to bolster recovery, enhance cognitive abilities, and promote general well-being.
On Behalf of the Board of Directors
“Pratap Sandhu”
Pratap Sandhu
CEO, Corporate Secretary and Director
+1 (604) 765-8069
Forward-Looking Information
This press release includes statements and information concerning future prospects, as defined by relevant securities legislation. These refer to upcoming occurrences or projected performance. Any statement not purely historical in nature could be considered a forward-looking statement or piece of information. Such forward-looking declarations and data are founded on specific primary expectations and suppositions made by the Company’s leadership. Consequently, there is no guarantee that the acquisition or associated activities will proceed as outlined or even occur. While the Company’s management deems the expectations and assumptions supporting these forward-looking statements and information to be sound, caution should be exercised against placing excessive trust in them, as their accuracy cannot be assured.